Braxia Scientific Corp.

Recent News

  • Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine and Psychedelics Clinical IP

    Toronto, Ontario--(Newsfile Corp. - March 16, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC PINK: BRAXF) (FWB: 4960) ("Braxia", or the "Company"), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, announces that Irwin Naturals Inc. ("Irwin") has terminated the non-binding amended and restated letter of intent ("LOI") for a business combination between Irwin and Braxia (the "Proposed Transaction"). Full details of the Proposed Transaction were contained in the Company's...

    2023-03-16 7:30 AM EDT
  • Braxia Scientific Reports Q3 2023 Financial Results and Provides Update on Acquisition Under LOI with Irwin Naturals

    Braxia Health ketamine treatments up 29% YoY in Q3 2023 and revenue up 50.5% YoYToronto, Ontario--(Newsfile Corp. - March 1, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the third quarter ended December 31, 2023. The Company...

    2023-03-01 8:35 PM EST
  • Braxia Scientific Announces Closing of First Tranche of LIFE Offering and Concurrent Private Placement

    Toronto, Ontario--(Newsfile Corp. - February 27, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia", or the "Company"), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, is pleased to announce that it has closed the first tranche of its non-brokered offering, as described in its press release of February 7, 2023 (the "LIFE Offering"), resulting in the issuance of 13,658,524 units of the Company (each a "Unit") at a...

    2023-02-27 8:34 PM EST
  • Braxia Scientific Announces Offering up to $1.5 Million, Braxia Management to Participate in Concurrent Private Placement

    Toronto, Ontario--(Newsfile Corp. - February 7, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC: BRAXF) (FSE: 4960) ("Braxia", or the "Company"), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, is pleased to announce an offering of up to 27,272,727 units of the Company (the "Units") at a price of $0.055 per Unit for aggregate gross proceeds of up to $1,500,000.00 pursuant to the listed issuer financing exemption (the "LIFE Offering") and a concurrent...

    2023-02-07 7:57 AM EST
  • RETRANSMISSION: Irwin Naturals Signs Letter of Intent to Acquire Braxia Scientific

    Strategic transaction assembles an experienced management and scientific team world-renowned in mental health treatment, research and developmentEstablishes large footprint of 17 specialized mental health clinics across North America, enhanced by a telehealth platform expected to extend access to critical treatments for millions of people across multiple states in the USCombined network of clinics creates a leading international mental health research platform for in-human clinical development of novel therapeuticsToronto, Ontario--(Newsfile Corp. - January 30, 2023) - Braxia Scientific Corp. (CSE: BRAX)...

    2023-01-30 7:32 AM EST
  • Irwin Naturals Signs Letter of Intent to Acquire Braxia Scientific

    Strategic transaction assembles an experienced management and scientific team world-renowned in mental health treatment, research and developmentEstablishes large footprint of 17 specialized mental health clinics across North America, enhanced by a telehealth platform expected to extend access to critical treatments for millions of people across multiple states in the USCombined network of clinics creates a leading international mental health research platform for in-human clinical development of novel therapeuticsToronto, Ontario--(Newsfile Corp. - January 27, 2023) - Braxia Scientific Corp. (CSE: BRAX)...

    2023-01-27 7:31 AM EST
  • Irwin Naturals and Braxia Scientific Sign Letter of Intent Entering Partnership to Launch In-Human Clinical Studies to Support Pharmaceutical Sponsors Across U.S.

    Toronto, Ontario--(Newsfile Corp. - January 10, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC PINK: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company"), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, is proud to announce it has signed a Letter of Intent entering into a partnership with Irwin Naturals Inc. ("Irwin") (CSE: IWIN) (OTC: IWINF) (FRA: 97X) to launch Clinical Research Services across Irwin's growing U.S. based network of clinics, Emergence. The partnership...

    2023-01-10 7:46 AM EST